ASCO
Refine Search
Biotechnology
Shares of Replimune closed up nearly 28% at $7.11 on Thursday after the company shared data on its oncolytic virus RP1 (vusolimogene oderparepvec), in combination with Bristol Myers Squibb’s Opdivo (nivolumab), 7 June 2024
Biotechnology
Gilead subsidiary Kite Pharma has announced updated four-year survival data from the ZUMA-3 study of Tecartus (brexucabtagene autoleucel). 5 June 2024
Biotechnology
Treos Bio, a biotech using data science and proprietary biomarkers to develop precision peptide immunotherapies, has presented results from its Phase II OBERTO-301 study. 4 June 2024
Biotechnology
US drugmaker AbbVie is keen not to be left behind in oncology’s antibody-drug conjugate (ADC) race. 4 June 2024
Biotechnology
French pharma major Sanofi released positive new data from the IMROZ Phase III study at the American Society of Clinical Oncology (ASCO) annual meeting. 4 June 2024
Biotechnology
Japanese pharma giant Takeda and Pfizer have announced positive results from the Phase III HD21 trial at the annual meeting of the American Society of Clinical Oncology (ASCO). 3 June 2024
Biotechnology
Faced with plenty of competition from other drugmakers at the 2024 American Society of Clinical Oncology (ASCO) meeting, Novartis has sought to show the strength of its cancer medicines with its latest data. 3 June 2024
Pharmaceutical
USA-based tumor drug resistance specialist Deciphera Pharmaceuticals today announced results from the company’s MOTION pivotal Phase III study of vimseltinib in patients with Tenosynovial Giant Cell Tumor TGCT) in an oral presentation at ASCO. 3 June 2024
Biotechnology
Positive results have been presented from the LAURA Phase III trial on AstraZeneca’s Tagrisso (osimertinib) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. 3 June 2024
Pharmaceutical
Eli Lilly has released updated data from its Phase I/II clinical trial evaluating olomorasib. 3 June 2024
Pharmaceutical
At the 2024 annual meeting of the American Society of Clinical Oncology (ASCO), Bristol Myers Squibb has announced promising results from the Phase III KRYSTAL-12 study. 3 June 2024
Biotechnology
US biotechs Gilead Sciences and Arcus Biosciences on Saturday announced longer-term efficacy and safety results from Arm A1 of the Phase II EDGE-Gastric study. 3 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Researchers from UK-based biotech Immunocore Holdings shared new data at the American Society of Clinical Oncology (ASCO) meeting on Kimmtrak (tebentafusp-tebn), the first-ever treatment approved for metastatic uveal melanoma (mUM), showing there is treatment benefit for patients with stable disease and any confirmed tumor reduction. 3 June 2024
Pharmaceutical
US cancer-focussed firm Karyopharm Therapeutics presented updated exploratory subgroup analyses from the Phase III SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the American Society of Clinical Oncology (ASCO). 2 June 2024
Biotechnology
US healthcare giant Johnson & Johnson (NYSE: JNJ) released new data from the Phase III MARIPOSA study demonstrating the efficacy of first-line treatment with Rybrevant (amivantamab) in combination with lazertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. 1 June 2024
ASCO 2024
]S pharma giant Pfizer was trading more than 1% higher during Friday morning’s New York activity. 31 May 2024
Biotechnology
With the annual meeting of the American Society of Clinical Oncology (ASCO) now just days away, multiple large drugmakers have lifted the lid on data that they intend to present. 29 May 2024
Biotechnology
The annual meeting of the American Society of Clinical Oncology (ASCO) is set to commence on 2 June in Chicago, with the highly anticipated plenary session taking place on the Sunday. 22 May 2024
Pharmaceutical
Swiss cancer giant Novartis and German drugmaker Bayer are among the latest companies to lift the lid on upcoming data presentations at ASCO 2024. 17 May 2024
Biotechnology
New data has been presented at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from three post-hoc subgroup analyses with German pharma major Bayer’s Vitrakvi (larotrectinib). 3 June 2023
Biotechnology
Building on the extraordinary success of its platform in producing an effective coronavirus vaccine, German mRNA specialist BioNTech is making inroads on a project which broadens its focus to include checkpoint inhibition. 2 June 2023
Biotechnology
Swiss pharma giant Novartis kicked off its 2023 American Society of Clinical Oncology (ASCO) presentations today, with much anticipated positive primary endpoint data from the pivotal Phase III NATALEE trial on Kisqali (ribociclib) in early breast cancer (EBC). 2 June 2023
Pharmaceutical
As the crowds descend on Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO), The Pharma Letter interviews Eisai chief medical officer Kirk Shepard about his firm’s progress in oncology. 1 June 2023
Pharmaceutical
This year’s meeting of the American Society of Clinical Oncology (ASCO) kicks off on Friday, with the highly anticipated plenary session taking place on Sunday. 31 May 2023
Pharmaceutical
In the runup to this year’s meeting of the American Society of Clinical Oncology (ASCO), drugmakers around the world are lifting the curtain on the data they plan to present at the event. 31 May 2023
Pharmaceutical
Privately-held Italian drugmaker Menarini has announced results from a new analysis of the pivotal EMERALD clinical study that suggest that oral single-agent Orserdu (elacestrant) may be effective in ER+, HER2- advanced or metastatic breast cancer patients with non-detected ESR1-mut whose disease has progressed within six months of treatment with a CDK4/6i. 30 May 2023
Pharmaceutical
US pharma giant Pfizer is to present data on more than 15 drugs—including six early pipeline assets—at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 through June 6. 25 May 2023
Biotechnology
Anglo-Swedish drugmaker AstraZeneca is lining up the big-hitters from its cancer drug portfolio for next week’s American Society of Clinical Oncology (ASCO) Annual Meeting. 25 May 2023
Biotechnology
Positive data for a new kind of cancer med, targeting the CLDN18.2 biomarker, will be presented at the March Plenary Series of the American Society of Clinical Oncology (ASCO). 22 March 2023
Pharmaceutical
Today, a new barometer survey from Sermo, a physician-first online community and leader in global HCP insights, timed to the conclusion of the annual American Society of Clinical Oncology (ASCO) conference found that the tracks oncologists found the most practice-changing were breast cancer (58%), lung cancer (34%), and developmental therapeutics – molecularly targets agents and tumor biology (32%). 7 July 2022
Biotechnology
Over the past few years, CAR T-cell therapies have also become transformative treatment options for patients with many forms of blood cancers, such as lymphoma and multiple myeloma. The treatment method involves taking a patient's T cells, "re-engineering" them to kill cancer cells, and infusing them back into the patient. 13 June 2022
Biotechnology
Last week’s news saw a lot of coverage of the American Society of Clinical Oncology (ASCO) meeting, among which the presentation of Phase III data on Enhertu by AstraZeneca and Daiichi Sankyo was viewed as especially important. Almirall and partner Eli Lilly on Tuesday released impressive new data on their lebrikizumab in the treatment of dermatitis. US Food and Drug Administration advisory committee meetings also attracted a good deal of attention. First, an AdCom voted overwhelmingly for the grant of emergency use authorization of Novavax’ COVID-19 vaccine Nuvaxovid. Thursday and Friday saw consecutive positive outcomes for bluebird bio’s gene therapies, first for its elivaldogene autotemcel (eli-cel) and then for beta-thalassemia candidate betibeglogene autotemcel (beti-cel). 12 June 2022
Biotechnology
Dostarlimab, an anti–PD-1 monoclonal antibody marketed by GSK under the brand name Jemperli, has shown impressive results in mismatch repair–deficient stage II or III rectal adenocarcinoma. 7 June 2022
Biotechnology
Swiss pharma major Novartis today announced longer-term follow-up data from the Phase III ASCEMBL trial for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors (TKIs), presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. 7 June 2022
Biotechnology
Even as generic competition gathers, the treatment landscape in multiple myeloma will likely be dominated by Bristol Myers Squibb’s Revlimid (lenalidomide) for some time to come. 7 June 2022
Biotechnology
The Johnson & Johnson subsidiary Janssen has presented data in multiple myeloma and mantle cell lymphoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. 6 June 2022
Biotechnology
Bristol Myers Squibb has presented two lots of data on its immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. 6 June 2022
Biotechnology
Kite, a subsidiary of US biotech major Gilead Sciences, over the weekend announced longer-term follow-up results from two pivotal studies of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel). 6 June 2022
Biotechnology
Detailed positive results from the pivotal DESTINY-Breast04 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated superior and clinically-meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients with HER2-low (immunohistochemistry (IHC) 1+ or IHC 2+/in-situ hybridization (ISH)-negative) unresectable and/or metastatic breast cancer with hormone receptor (HR) positive or HR-negative disease versus standard of care physician’s choice of chemotherapy. 6 June 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze